INT183186

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2005
Last Reported 2009
Negated 2
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.26
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Mip) plasma membrane (Mip) transmembrane transport (Mip)
Anatomy Link Frequency
myotubes 1
Mip (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 5 87.28 High High
chemokine 43 78.96 Quite High
tolerance 1 7.36 Low Low
Inflammation 23 5.00 Very Low Very Low Very Low
cytokine 20 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
corticosteroid 2 5.00 Very Low Very Low Very Low
alcohol 2 5.00 Very Low Very Low Very Low
Inflammatory response 2 5.00 Very Low Very Low Very Low
Inflammatory stimuli 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypercalcemia 59 98.24 Very High Very High Very High
Solid Tumor 3 84.24 Quite High
Reprotox - General 1 1 83.28 Quite High
Breast Cancer 4 82.60 Quite High
Metastasis 2 81.84 Quite High
Multiple Myeloma 9 77.60 Quite High
Sepsis 26 73.84 Quite High
Cancer 47 64.48 Quite High
Pseudomonas Infection 4 63.64 Quite High
Disease 17 57.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
With regard to targeting MIP-1?
Regulation (targeting) of MIP
1) Confidence 0.26 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924519 Disease Relevance 1.06 Pain Relevance 0.08
However, exposure of the cultured diaphragmatic myotubes to LPS markedly upregulated RANTES (see Figure 4(a)) but had no measurable effect on MIP-1?
Neg (no) Regulation (effect) of MIP in myotubes
2) Confidence 0.26 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2676322 Disease Relevance 0.14 Pain Relevance 0.13
However, the value of SVL and aspiration in addition to the other techniques seemed too small to warrant the effort.
Regulation (value) of SVL
3) Confidence 0.13 Published 2008 Journal BMC Pulm Med Section Body Doc Link PMC2267157 Disease Relevance 0.06 Pain Relevance 0
Figure 5A demonstrates graphically that the COX-2 USE oligoribonucleotide specifically inhibited SVL polyadenylation in vitro, whereas a non-specific oligoribonucleotide had no significant effect on SVL polyadenylation.
Neg (no) Regulation (effect) of SVL
4) Confidence 0.02 Published 2005 Journal Nucleic Acids Research Section Body Doc Link PMC1088970 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox